Version 1.0.3

Submission Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/04/2016
Deadline Date	29/04/2016
Date Submitted	27/04/2016
Type	Historic Performance in Initiating
NHS provider	Maidstone and Tunbridge Wells NHS Trust

Showing records 1 to 25 of 33. Pages: 1 2 Next >

http:/	7	7			I.
Innfate	8609 1	8608	8607 1	'8606	
hihr an Ilk	78609 15/LO/1807 187302	78608 15/WM/0457 195511	78607 10/H1313/2	78606 14/EM/0172 142310	Research Ethics Committee Reference Number
Submissio			21860	142310	Integrated Research Application System Number
n acny 2Mad	NHS Permission	NHS Permission	NHS Permission	NHS Permission	
http://coforta nibr ac uk/Submission acry/MataSubmission/d= 278 Submission/d= 22668 Teuritud= 1110	Checkmate 331 An Open-label, Prandomized, Phase 3 study of Nivolumab or chemotherapy in subjects with	DARATUMUMAB: An Open-Label Treatment Use Protocol for Subjects with Mulitple Muyeloma Who Have Received at Least 02/03/2016 3 Prior Lines of Therapy (Including a Proteassome Inhibitor and an Inmunomodulatory Agent) or are Double Refractory to a Proteas	LuCID: Longitudinal European Clostridium difficile Injection Diagnosis	BABY OSCAR- Outcome after Selective early Treatment for Closure of patient Ductus Arteriosus in Pre-term babies.	Submission Name of Trial Type
78. Submice	25/01/2016	02/03/2016	27/08/2015	13/10/2015	Date of Receipt of Valid Research Application
ionId= 3365	23/02/2016 No	10/03/2016 Yes	27/08/2015 No	12/02/2016	Date of First NHS Patient Permission Recruited?
8. Tructle-1	8		No	No	First Patient Recruited?
110		22/03/2016 8			Date of First Patient Recruited
	29		15	122	Duration between VRA and NHS Permission
		12			Duration Dur between bet NHS VR, Permission and and First Firs Patient Pat
		20			ation ween A A ient
					tion een Site Site cted Date
					Duration Du between be Date Site Da Confirmed Se and First an Patient Pa Recruited Re
	Day	ĕs	No	No	Duration between Date Site Selected Patient Recruited
	Within 70 Days				chmark
3					te Date e Site vited Selecte
5					Date Date HRA Site Site Approval Invited Selected Date
					Date Site Confirmed By Sponsor
	40.77				d
	Please Select	Select	Please Select	Please Select	Non- Confirmat Status

1/6

	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	7	4	2	1
78614 1	78613 1	8612.1	8611	8610 13	
14/NW1258				3/EM/0348	
161891	142447	135504			
NHS Permission	NHS Permission	NHS Permission			
ARAMIS 3104007 ORION - A multicentre, randomised, double-blind, placebo-controlled, pl	UNIRAD: Randomized, doubled-blind, multicentre phase 111 trail evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2 - primary breast cancer who remain free of disease after receiving	ProCaid: An open phase 1/randomised, double-blind phase 11 study in metastatic castration resistant Prostate Cancer of AZD5363 in combination with Docetaxel and prednisolone chemotherapy.	InterAACT - A Multicentre Randomised Phase 11 Advanced Anal Cancer Trial	Monoprost compared with Lumigan in POA glaucoma/ocular hypertention	replases small-cell lung cancer after Platinum- Based first line chemotherapy. CA209-331
02/04/2015	06/03/2016	02/04/2015	09/06/2015	26/10/2015	
01/05/2015	09/03/2016	16/06/2015	16/07/2015	30/10/2015	
Zo	Z.	Z _o	Z	No.	
29	ω	75	37	4	
2 o	Within 70 Days	8	6	6	
		N			
Please Select	Please Select	Please Select	Please Select	Please Select	
	ARAMIS 3104007 ARION - A multicentre, randomised, double-blind, double-blind, placebo-controlled, placebo-c	142447 NHS Giudiod-biring, multicentre phase the selful of adding benefit of adding the selful of adding	195504 MNS prase prase (nucleoting) 10002015 No 75 VMS probatic (nucleoting) 10002015 No 76 No VMS probatic (nucleoting) 10002016 No 3 No VMS probatic (nucleoting) 10002016 No 3 No VMS probatic (nucleoting) 10002016 No 1 1 VMS probatic (nucleoting) 10002016 No 1 1 VMS probatic (nucleoting) 10002016 No 1 1 VMS probatic (nucleoting) 1000201	Instant Instant <t< td=""><td>132371 Newson Results (submitting) Nonconstitution (submitting) Nonconstitution (submi</td></t<>	132371 Newson Results (submitting) Nonconstitution (submitting) Nonconstitution (submi

CTP Submission Platform - Submission (Version 1.0.3)

2/5/2018

http					
://ccfctį	78618 1	78617 1	78616	78615	
p.nihr.ac.uk	78618 15/LO/0016	78617 15/EM/0344 183906	78616 14/LO/1043	78615 14/WM/1055 152229	
/Submissio	164539	183906	137864	152229	
on.aspx?Me	NHS Permission	Permission	Permission	Permission	
http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=37&SubmissionId=3365&TrustId=1119	MONARCH 3: A Randomised, Double-Bind, Placebo- Controlled, Phase 3 Study of Nonsteroidal Atomatase Inhibitor (Anastrozole or Letrozole) Plus (2783219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with			AB12006 - A prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group, phase 3 study to compare the efficacy and safety of masitnib in combination with FOLFIRI (innotecan, 5- flurouracil and folinic acid) to placebo in com	men with high risk non-metastatic castration-resistant prostate cancer.
7&Submiss	29/04/2015	14/03/2016	15/05/2015	10/07/2015	
sionId=3365	28/05/2015	23/03/2016	18/06/2015	23/07/2015	
5&TrustId=	8	Z	Yes	Yes	
1119			01/10/2015 34	01/12/2015 13	
	29	ω	4	ದೆ	
			105	131	
_			13g	144	÷
-					
-					
-	z	Day	Z _o	2	
-		Within 70 Days			
_					
-					
_					
3/6	Please Select	Please Select	Please Select	Please Select	

CTP Submission Platform - Submission (Version 1.0.3)

2/5/2018

	7862	78621	78620	78619	
	78622 14/LO/1206	78621 14/LO/1291	78620 15/LO/0940	78619 14/SC/0171 120104	
	154428	148513	179018	120104	
	NHS Permission	NHS Permission	Permission	NHS Permission	
CALM-NET: A Phase 4, Multicentre, Open label, Single Group Exploratory Study to Assess the	CCR3804 PLATFORM: Planning treatment for oesophago- gastric cancer. a maintenance trial.	PALLET - A phase 11 randomised study evaluating the biological and clinical effects of the combination of palociclib with letrozole as neo adjuvant therapy in post-menopausal women with ER+ primary breast cancer.		Add - Aspirin: A phase III double- blind placebo - controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after therapy in common non-metastatic solid tumours.	Hormone Receptor-Positive, HER2-Negative Lo
	26/06/2015	16/09/2015	13/11/2015	10/07/2015	
	27/07/2015	20/10/2015	22/12/2015	27/07/2015	
	Zo	S	ō	Yes	
				15/12/2015 17	
	ŭ	34	ů B	17	
				14	
				58	
	Z o	R R R R R R R R R R R R R R R R R R R	8	No N	
	Please Select	Please Select	Please Select	Please Select	

http://	78	2	2	7	7	51
ccfctp.	3628	8627 15	8626 14	8625	1:	78623
nihr.ac.uk	78628 14/SC/0092	78627 15/EM/0400 178129	78626 14/LO/0100	78625 15/LO/0691	78624 13/NW/0153 104669	78623 13/LO/1557
/Submissio	148386	178129	135429	174324	104669	135995
on.aspx?Met	NHS Permission	Permission	NHS Permission	Permission	Permission	NHS Permission
http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=37&SubmissionId=3365&TrustId=1119	LASER: Laminator Airflow in Severe Asttma for Exacerbation Reduction. A multi-centre, randomised, double-blind, double-blind, parallel group trial of the effectiveness of	SOPHIA - A Phase 3. Randomised Study of Margetuximab Plus Chemotherapy vis Trastruzumab Plus Chemotherapy in the Treatment of Patients with HER2+Metastatic Breast Cancer Who Have Received Two Prior AntI-HER2 therapies and Require Systemic Treatment	APIPPRA - Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept	CHECKMATE 171: BMS-396558 A Safety Trial of Nivolumab (BMS- 936558) in Subjects With Advanced or Metastatic Non- Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen	CIPHER: Phase 11 multicentre study assessing the efficacy of Cabazitaxel in patients with HER2-negative metastatic breast cancer and having un-resectable brain metastases.	Clinical Value of Enumeration of Circulating Turnour 21/04/2015 2 Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep S
7&Submiss	30/06/2015	16/02/2016	02/11/2015	27/07/2015	16/02/2016	- 21/04/2015
ionld=3365	07/07/2015	25/02/2016	04/11/2015	03/09/2015	23/02/2016	21/05/2015
%TrustId=1	Yes	Z	Yes	8	Z _o	N _o
119	21/08/2015 7	10	31/12/2015 :			
		Q	N	8	7	30
	45		57			
	55 N		59			
-						
-						
-	Yes	Day	Yes	Z		<mark>8</mark>
-		Within 70 Days			Within 70 Days	
-						
-						
_						
;	Please Select	Please Select	Please Select	Please Select	Please Select	Please Select

http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=37&SubmissionId=3365&TrustId=1119

CTP Submission Platform - Submission (Version 1.0.3)

2/5/2018

78630 12/WA/0374 98726 NHS Permission NHS techniques to 18/02/2016 No 5
HART Hughes Abdominal Repair Trial - Abdominal wall closure techniques to 18/02/2016 23/02/2016 No

Showing records 1 to 25 of 33. Pages: $1 \ge \frac{Next}{2}$

< Back

Copyright (c) Exbos Limited 2013. All Rights Reserved. Web site developed in the City of Leeds, England by Exbos Limited the bespoke software specialists.

ාexbos

http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=37&SubmissionId=3365&TrustId=1119